[ASAP] PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models

TOC Graphic

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.3c01781

Source link

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts